×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Kinnate Biopharma Earnings Date, Estimates & Call Transcripts (2022)

$12.75
+0.14 (+1.11%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.38
$12.99
50-Day Range
$7.43
$13.00
52-Week Range
$7.18
$26.05
Volume
77,074 shs
Average Volume
170,793 shs
Market Capitalization
$560.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.80

Earnings Summary

Upcoming
Earnings Date
Aug. 15Estimated
Actual EPS
(May. 12)
-$0.61 Beat By $0.01
Consensus EPS
(May. 12)
-$0.62
Last Year's Q2 EPS
(5/17/2021)
-$0.40
Skip Charts & View Estimated and Actual Earnings Data

KNTE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KNTE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Kinnate Biopharma Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20225($0.65)($0.57)($0.61)
Q2 20225($0.73)($0.47)($0.60)
Q3 20225($0.77)($0.53)($0.65)
Q4 20225($0.83)($0.59)($0.69)
FY 202220($2.98)($2.16)($2.55)
Q1 20232($0.87)($0.58)($0.73)
Q2 20232($0.94)($0.51)($0.73)
Q3 20232($0.97)($0.52)($0.75)
Q4 20232($1.00)($0.57)($0.79)
FY 20238($3.78)($2.18)($2.98)

KNTE Earnings Date and Information

Kinnate Biopharma last issued its earnings results on May 12th, 2022. The reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.01. Kinnate Biopharma has generated ($2.27) earnings per share over the last year (($2.27) diluted earnings per share). Earnings for Kinnate Biopharma are expected to decrease in the coming year, from ($2.55) to ($2.85) per share. Kinnate Biopharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 15th, 2022 based off prior year's report dates.

Kinnate Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/15/2022
(Estimated)
        
5/12/2022Q1 2022($0.62)($0.61)+$0.01($0.61)    
3/28/2022Q4 2021($0.60)($0.60)($0.60)
11/10/20219/30/2021($0.53)($0.57)($0.04)($0.57)
8/15/20216/30/2021($0.43)($0.49)($0.06)($0.49)    
5/17/2021Q1 2021($0.37)($0.40)($0.03)($0.40)












Kinnate Biopharma Earnings - Frequently Asked Questions

When is Kinnate Biopharma's earnings date?

Kinnate Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 15th, 2022 based off last year's report dates. Learn more on KNTE's earnings history.

Did Kinnate Biopharma beat their earnings estimates last quarter?

In the previous quarter, Kinnate Biopharma (NASDAQ:KNTE) reported ($0.61) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.62) by $0.01. Learn more on analysts' earnings estimate vs. KNTE's actual earnings.

How can I listen to Kinnate Biopharma's earnings conference call?

The conference call for Kinnate Biopharma's latest earnings report can be listened to online. Listen to Conference Call

How can I read Kinnate Biopharma's conference call transcript?

The conference call transcript for Kinnate Biopharma's latest earnings report can be read online. Read Transcript

How much profit does Kinnate Biopharma generate each year?

Kinnate Biopharma (NASDAQ:KNTE) has a recorded net income of -$89.76 million. KNTE has generated -$2.27 earnings per share over the last four quarters.

What is Kinnate Biopharma's EPS forecast for next year?

Kinnate Biopharma's earnings are expected to decrease from ($2.55) per share to ($2.85) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:KNTE) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.